Kurin, Inc.

38 articles about Kurin, Inc.

• Kurin, Inc. Reports Record Revenue for Q1 2024

  4/3/2024

  Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the first quarter of 2024, following a record 2023.

• Kurin, Inc. Reports Record Revenue for Q3 2023

  10/5/2023

  Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the third quarter of 2023.

• Kurin, Inc. Named 2023 Diverse Supplier of the Year by Vizient

  9/27/2023

  Kurin, Inc. has been named the 2023 Diverse Supplier of the Year by Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company.

• USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

  8/15/2023

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.

• Delaware Federal Court Issues a Stay Order in Patent Dispute between Magnolia Medical and Kurin, Inc.

  8/10/2023

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provided an update on the ongoing patent infringement case brought against Kurin by Magnolia Medical.

• Kurin Launches Kurin Jet, Redefining the Blood Culture Contamination Device Market

  7/12/2023

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced the full-scale launch of Kurin Jet, which has joined the Kurin Lock family.

• USPTO Agrees to Kurin’s Request to Review Validity of Magnolia Medical’s ‘483 Patent

  5/3/2023

  Kurin, Inc. announced that the US Patent and Trademark Office has granted Kurin’s Ex Parte request to reexamine the validity of U.S. Patent No. 10,039,483 that is asserted by Magnolia Medical in ongoing patent litigation.

• Kurin Receives 510k from the FDA with Indication to Reduce Blood Culture Contaminations

  5/2/2023

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the Food and Drug Administration has issued a 510(k) clearance for the Kurin product line. Kurin now has four 510(k) clearances from the FDA.

• Kurin Announces Kurin Jet, A Quantum Leap Forward in Devices Designed to Address Blood Culture Contamination

  2/15/2023

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced the limited commercial release of Kurin Jet™, a significant technological advance over Kurin’s own market-leading Kurin Lock®.

• Kurin, Inc. Reports Record Revenue for 2022

  1/26/2023

  Kurin, Inc., the inventor and manufacturer of the Kurin ® blood culture collection sets announced record revenues for 2022.

• Kurin, Inc. Announces Successful FDA Audit

  9/28/2022

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced the results of their recent FDA inspection.

• Kurin, Inc. Announces Full Scale Manufacturing of Push-button Needle

  9/7/2022

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that their previously mentioned Advance Safety Needle System™ has entered full scale production on their automated machine.

• Kurin, Inc. Statement Regarding Patent Litigation

  8/3/2022

  Kurin Inc., the inventor and manufacturer of 510-cleared Kurin® blood culture collection sets, released a statement regarding results of a jury trial in the patent litigation brought by Magnolia Medical Technologies.

• Magnolia Medical Technologies Wins Patent-Infringement Lawsuit against Kurin, Inc.

  7/29/2022

  A jury for the U.S. District Court of Delaware delivered two unanimous verdicts this week in favor of Magnolia Medical Technologies, Inc. ("Magnolia Medical") in a lawsuit against Kurin, Inc., ("Kurin") regarding the unlawful use of its innovative Initial Specimen Diversion Device® (ISDD®) technology.

• Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System

  2/23/2022

  Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets.

• Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures

  1/18/2022

  Kurin, Inc., the inventor and manufacturer of 510-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO.

• Kurin, Inc. Announces UK Clinical Study Results Showing Significant Decrease in Blood Culture Contaminations With the Kurin Lock™

  10/5/2021

  Kurin, Inc., the inventor and manufacturer of 510-cleared Kurin® blood culture collection sets, announced a new clinical study supporting the efficacy of their blood culture collection product.

• Kurin, Inc. Reports Record Sales Month

  8/10/2021

  Kurin Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that July revenues represent their highest monthly total in their history.

• Kurin, Inc. Announces Results on Kurin® Efficacy From Oishei Children’s Hospital With Zero Blood Culture Contaminations

  7/21/2021

  Kurin Inc., the inventor and manufacturer of 510-cleared Kurin® blood culture collection sets, announced that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference.

• Kurin, Inc. Named to Inc.'s Inaugural Best in Business List in the Prosperous and Thriving Category

  12/8/2020

  Kurin, Inc. has been named to Inc.’s inaugural Best in Business list in the Prosperous and Thriving category.